The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample.

Cannabis use is highly prevalent among people with schizophrenia, and coupled with impaired cognition, is thought to heighten the risk of illness onset. However, while heavy cannabis use has been associated with cognitive deficits in long-term users, studies among patients with schizophrenia have been contradictory. This article consists of 2 studies. In Study I, a meta-analysis of 10 studies comprising 572 patients with established schizophrenia (with and without comorbid cannabis use) was conducted. Patients with a history of cannabis use were found to have superior neuropsychological functioning. This finding was largely driven by studies that included patients with a lifetime history of cannabis use rather than current or recent use. In Study II, we examined the neuropsychological performance of 85 patients with first-episode psychosis (FEP) and 43 healthy nonusing controls. Relative to controls, FEP patients with a history of cannabis use (FEP + CANN; n = 59) displayed only selective neuropsychological impairments while those without a history (FEP - CANN; n = 26) displayed generalized deficits. When directly compared, FEP + CANN patients performed better on tests of visual memory, working memory, and executive functioning. Patients with early onset cannabis use had less neuropsychological impairment than patients with later onset use. Together, these findings suggest that patients with schizophrenia or FEP with a history of cannabis use have superior neuropsychological functioning compared with nonusing patients. This association between better cognitive performance and cannabis use in schizophrenia may be driven by a subgroup of "neurocognitively less impaired" patients, who only developed psychosis after a relatively early initiation into cannabis use.

Eating and weight related cognitions in people with Schizophrenia: a case control study

ABSTRACT: BACKGROUND: Patients with antipsychotic-induced weight gain (WG) regularly report on unsuccessful dietary trials, which suggests strong biological weight gain drive that is extremely hard to overcome with thoughts, such that behaviour doesn't change despite some intent to change. The purpose of the present study was to assess cognitions specifically related to restrained eating in severely overweight patients with schizophrenia treated with antipsychotic drugs. METHODS: Forty outpatients with schizophrenia and 40 controls without psychiatric disability were included. Both groups were composed of one subgroup severely overweight (defined as a BMI > 28), and a comparison sample (BMI<28). The revised version of the Mizes Anorectic cognitive questionnaire (MAC-R) was used in this cross-sectional case-control study. RESULTS: Gender was significantly related to eating disorders cognition, women scoring higher than men. Patients with schizophrenia in general scored higher on the MAC-R total scale and on the MAC-R subscale 2, the latter score representing rigid weight regulation and fear of weight gain. When comparing the two groups of subjects with BMI < 28, it appeared that patients with schizophrenia also scored higher on MAC-R total scale, the subscales 2 and 3, the latter subscale 3, indicating altered self control and self-esteem. CONCLUSION: As is the case in weight gain of subjects without schizophrenia, the present results suggest that the cognitive distortions, as assessed by the MAC-R, may play an important role in weight gain also in patients with schizophrenia, and in weight gain associated with antipsychotic pharmacotherapy. Particular attention to these processes may help to improve the management of antipsychotic drugs induced weight gain

Extraits de manuscrits de COLBERT.

Contient : Colb. 1548 [lat. 3858 B] : collection de canons ; Colb. 1562 [lat. 4172] : formulaire de lettres pontificales, XIVe-XVe siècle ; Colb. 1701 [lat. 4863] : catalogue en vers des archevêques de Rouen ; Colb. 1713 [lat. 937] : formulaire de la chancellerie des papes d'Avignon ; Colb. 1995 [lat. 4667] : catalogue des rois goths ; Colb. 2052 [lat. 2259] : bulles et diplômes du XIIIe siècle ; Colb. 2089 [lat. 4241] : traité de Jean Schadlant sur les cardinaux ; Colb. 2104 [lat. 5990] : bulles en faveur des rois de France ; Colb. 2262. [lat. 5244] : martyrologe de l'église du Puy ; Colb. 2275 [lat. 9996] : registre de la sénéchaussée de Carcassonne ; Colb. 2446 [lat. 8567] : Etienne de Saint-Georges ; Colb. 2479 [lat. 1772] : « planctus in obitum Constantii Luxoviensis » ; Colb. 2509 [lat. 5294] : miracles de saint Mansuy ; Colb. 2546 [lat. 5373 A] : procès de canonisation de Philippe, archevêque de Bourges ; Colb. 2576 [lat. 1458] : « Gesta Romanorum pontificum » ; Colb. 2578 [lat. 4955] : catalogues épiscopaux ; Colb. 2607 [lat. 673] : extrait de Guibert de Nogent ; Colb. 2835 [lat. 4991 A] : Aimeri de Peyrat ; Colb. 2958 [lat. 5302] : lettre de Jésus-Christ tombée du ciel ; Colb. 3126 [lat. 5954] : traités entre les rois de France et d'Angleterre ; Colb. 3280 [lat. 1745] : « Herberti, De hereticis » ; Colb. 3352 [lat. 8121 A] : satire de Garnier de Rouen ; Colb. 3969 [lat. 6042] : catalogues épiscopaux de la province de Reims ; Colb. 4001 [lat. 7185] : « Arithmomachia » ; Colb. 4047 [lat. 3881] : recueil de canons ; Colb. 4064 [lat. 1682] : recueil de décrétales ; Colb. 4085 [lat. 2731 A] : lettre d'Alcuin ; Colb. 4305 et 4309 [lat. 4280 AA et 2240] : traité contre les hérétiques ; Colb. 4374 [lat. 4889] : chronique d'Ekkehard ; Colb. 4467 [lat. 4350] : lettres de Boniface VIII ; Colb. 4799 [lat. 3555] : recueil d'Exempla ; Colb. 4822 [lat. 8654] : formulaire de Boncompagni ; Colb. 4967 [fr. 5909] : pièces relatives au règne de Charles III ; Colb. 5016 [lat. 2498] : vie de sainte Hélène ; Colb. 5080 [lat. 11015] : chartes de Narbonne ; Colb. 5222 [lat. 2858] : pièces concernant la marche d'Espagne ; Notes écrites par François Bohier, évêque de Saint-Malo [1535-1569] sur les feuillets blancs d'un pontifical ; Chartes de Philippe-Auguste pour Baudouin, comte de Flandre, 1195 et 1200 [Delisle, nos 447 et 579], d'après les originaux ; Bulle de Jean XXII, 7 juillet 1316, relative à la division du diocèse de Toulouse ; Fragment de synode sénonais de la fin du Xe siècle, d'après l'original ; Lettre d'Alcuin, feuillet mutilé d'un ms. du IXe siècle, avec transcription (cf. Bibl. de l'Ecole des chartes, t. XLII, p. 8-10)

Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: A three-year study.

The trabecular bone score (TBS) is an index of bone microarchitectural texture calculated from anteroposterior dual-energy X-ray absorptiometry (DXA) scans of the lumbar spine (LS) that predicts fracture risk, independent of bone mineral density (BMD). The aim of this study was to compare the effects of yearly intravenous zoledronate (ZOL) versus placebo (PLB) on LS BMD and TBS in postmenopausal women with osteoporosis. Changes in TBS were assessed in the subset of 107 patients recruited at the Department of Osteoporosis of the University Hospital of Berne, Switzerland, who were included in the HORIZON trial. All subjects received adequate calcium and vitamin D3. In these patients randomly assigned to either ZOL (n = 54) or PLB (n = 53) for 3 years, BMD was measured by DXA and TBS assessed by TBS iNsight (v1.9) at baseline and 6, 12, 24, and 36 months after treatment initiation. Baseline characteristics (mean ± SD) were similar between groups in terms of age, 76.8 ± 5.0 years; body mass index (BMI), 24.5 ± 3.6 kg/m(2) ; TBS, 1.178 ± 0.1 but for LS T-score (ZOL-2.9 ± 1.5 versus PLB-2.1 ± 1.5). Changes in LS BMD were significantly greater with ZOL than with PLB at all time points (p < 0.0001 for all), reaching +9.58% versus +1.38% at month 36. Change in TBS was significantly greater with ZOL than with PLB as of month 24, reaching +1.41 versus-0.49% at month 36; p = 0.031, respectively. LS BMD and TBS were weakly correlated (r = 0.20) and there were no correlations between changes in BMD and TBS from baseline at any visit. In postmenopausal women with osteoporosis, once-yearly intravenous ZOL therapy significantly increased LS BMD relative to PLB over 3 years and TBS as of 2 years. © 2013 American Society for Bone and Mineral Research.

La mission de "la Cybèle" en Extrême-Orient, 1817-1818 / Journal de voyage du capitaine A. de Kergariou ; publié et annoté par Pierre de Joinville,...

Collection : Société de l'histoire des colonies françaises ; 3